relapsed or refractory peripheral T-cell lymphoma
Conditions
Interventions
elderly patients with relapsed or refractory perip:Treated with Gemcitabine, oxaliplatin and dexamethasone (GOD) regimen
Sponsors
Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. age >= 60 years and unsuitable for high dose therapy; 2. histologically confirmed diagnosis of peripheral T-cell lymphoma; 3. relapsed or refractory disease; 4. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2, expected life time >= 3 months; 5. signed informed consent.
Exclusion criteria
Exclusion criteria: 1. liver dysfunction:serum transaminases or bilirubin >= 2 times upper limit of normal value; 2. renal impairment: serum creatinine clearance <30 ml/min; 3. heart failure: left ventricular ejection fraction <0.45; 4. bone marrow suppression :absolute neutrophil count (ANC) <=1000/ul, hemoglobin level <=10 g/dl and platelets <=100000/ul; 5. uncontrolled infection; 6. positive human immunodeficiency virus tests.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate;toxicity evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;event-free survival; | — |
Countries
China
Contacts
Public ContactZhu Qi
Outcome results
None listed